Antegren Data Show 66% Reduction In Multiple Sclerosis Relapse Rate
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec and Elan are confident that one-year data will differentiate Antegren within the MS market. The companies have three weeks to familiarize prescribers and payors with natalizumab ahead of its estimated FDA action date at the end of the month.